Paper Details

  1. Home
  2. Paper Details

Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.

Author: , Ben-YehudaDina, BensingerWilliam I, DimopoulosMeletios A, Goranova-MarinovaVesselina, HájekRoman, JakubowiakAndrzej J, KukretiVishal, LudwigHeinz, MaisnarVladimír, MassziTamás, MateosMaria-Victoria, MihaylovGeorgi G, MinarikJiri, MoreauPhilippe, NiesvizkyRuben, OriolAlbert, PalumboAntonio, RajkumarS Vincent, RajnicsPéter, RosiñolLaura, San-MiguelJesus F, SiegelDavid S, StewartA Keith, SuvorovAleksandr, TondaMargaret E, WangMichael, XingBiao, YangXinqun, ZojwallaNaseem, ŠpičkaIvan

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Adding carfilzomib to lenalidomide and dexamethasone significantly improved progression-free survival in patients with relapsed multiple myeloma. The combination had a favorable risk-benefit profile and patients reported superior health-related quality of life.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Lenalidomide plus dexamethasone is a reference treatment for relapsed multiple myeloma. The combination of the proteasome inhibitor carfilzomib with lenalidomide and dexamethasone has shown efficacy in a phase 1 and 2 study in relapsed multiple myeloma. METHODS: We randomly assigned 792...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1056/NEJMoa1411321

データ提供：米国国立医学図書館（NLM）

Carfilzomib, Lenalidomide, and Dexamethasone: A Powerful Combination for Relapsed Multiple Myeloma

The journey of treating relapsed multiple myeloma, a complex and challenging cancer, often involves a combination of medications. This randomized, controlled trial investigates the efficacy and safety of adding the proteasome inhibitor carfilzomib to the standard treatment regimen of lenalidomide and dexamethasone for patients with relapsed multiple myeloma.

Carfilzomib's Impact on Progression-Free Survival

The study found that the addition of carfilzomib significantly improved progression-free survival compared to lenalidomide and dexamethasone alone. This finding suggests that carfilzomib can be a valuable addition to the treatment regimen for relapsed multiple myeloma.

Improving Outcomes in Relapsed Multiple Myeloma

The research highlights the potential of carfilzomib to enhance treatment outcomes for patients with relapsed multiple myeloma. It's like finding a hidden spring in the desert, providing a fresh source of hope and vitality for those battling this challenging disease.

Dr.Camel's Conclusion

This study provides compelling evidence for the use of carfilzomib in combination with lenalidomide and dexamethasone for the treatment of relapsed multiple myeloma. The combination therapy offers a significant improvement in progression-free survival and holds promise for enhancing the lives of patients with this challenging condition.

Date :
  1. Date Completed 2015-01-15
  2. Date Revised 2022-04-10
Further Info :

Pubmed ID

25482145

DOI: Digital Object Identifier

10.1056/NEJMoa1411321

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.